Abstract
Immunosuppressive therapy
All patients received immunosuppressive therapy comprising tacrolimus and steroids after liver transplantation. Oral tacrolimus administration was commenced at 0.5-1 mg every 12 h (q12h). The dosage was then empirically adjusted to attain steady-state C 0 within the range of 8-12 ng ml -1 in the first 3 months post-operation, 8-10 ng ml -1 between 3 and 6 months, and 6-8 ng ml -1 thereafter.
Intravenous methylprednisolone was administered at a dose of 500 mg on the operative day, followed by 80 mg q12h on postoperative days 1-3. Then, the dosage was tapered to 80 mg day -1 on postoperative days 4 and 5 followed by 40 mg day -1 on postoperative days 6 and 7. Thereafter, the dosage was reduced to 20 mg day -1 on postoperative days 8-10. Oral prednisolone was administered at a dosage of 12 mg day -1 on postoperative day 11 and was tapered to 4 mg day -1 at a rate of 4 mg day -1 , except for hepatocellular carcinoma patients with liver transplantation. During the second month after surgery, corticosteroid-free treatment was conducted, except for patients with autoimmune hepatitis.
Mycophenolate mofetil (CellCept, Roche Pharma Ltd., Shanghai, China) was administered orally q12h at 0.5 g day -1 to patients who had glomerular filtration rate (GFR) of less than 60 ml min -1 per 1.73 m 2 (Hao et al., 2014).
Blood sample collection and bioassay
After reaching a steady-state condition, whole blood samples were drawn before the morning dose for assaying C 0 using the enzyme multiplied immunoassay technique (EMIT) with SYVA Viva-Emit 2000 kit (Siemens Healthcare Diagnostics Inc., Germany). The coefficient of variation (% CV) of intra-and inter-day precisions was within 10% and 20%, respectively, with a calibration range between 2.0 and 30 ng ml -1 .
Diverse bioassays were performed in previous studies and systematic deviations existed among the different analysis The median prediction error (MDPE) and median absolute prediction error (MAPE) were applied to investigate the accuracy and precision of predictability, respectively. F 20 (PE% within ± 20%) and F 30 (PE% within ± 30%), an index of both accuracy and precision, were also calculated. If a model reached the criteria of MDPE ≤ ± 20%, MAPE ≤ 30%, F 20 ≥ 35%, and F 30 ≥ 50% (Mao et al., 2018; Zhang et al., 2019), its predictive performance was considered to be satisfactory and clinically acceptable.
Simulation-based diagnostics
To assess the predictability of each selected model based on simulation, prediction-and variability-corrected visual predictive check (pvcVPC) as well as normalised prediction distribution error (NPDE) test were conducted to compare the simulated and observed data. The dataset was simulated 2000 times using the $SIMULATION module of NONMEM ® .
The calculations and graphical visualisations for pvcVPC were performed with PsN. To identify systematic bias between the observed and simulated data, the 95% confidence intervals (CIs) for the median and the 5 th and 95 th percentiles of the simulated concentrations at different bins were calculated and compared with the observations. The bins were automatically selected by the VPC command in PsN. NPDE determination was implemented with the NPDE add-on package in R (version 2.0; www.npde.biostat.fr). Based on the null hypothesis that the evaluation data can be well described by a candidate model, NPDE follows a standard normal distribution.
Bayesian forecasting
Maximum a posteriori Bayesian (MAPB) forecasting was conducted using data from patients with ≥ 5 observations to evaluate the effect of priors on model predictive performance. For each patient, the individual prediction (IPRED) of the fifth observation was predicted by the last one, two, three, and four prior observations, and subsequently compared with the corresponding observation. Individual prediction error (IPE%) was calculated using equation (4) as follows:
To assess the predictability of a candidate model as the prior information increased, median IPE% (MDIPE), median absolute IPE% (MAIPE), and IF 20 and IF 30 , that represented F 20 and F 30 of IPE%, respectively, were computed under the circumstance of nought to four priors.
Influence of model structures
Considering that model structure was one of the primary factors affecting the predictive performance, the various structural models reported in previous studies were reviewed (Zhao et al., 2016) . The prediction-based diagnostics and Bayesian forecasting described above were employed to investigate the predictability of structural models.
Results

Review of published popPK analysis on tacrolimus
Sixteen popPK models for tacrolimus in adult liver transplant recipients (Antignac et CYP3A5 genotype of both recipients and donors, genetic polymorphisms of ABCB1 (C3435T) of recipients, concomitant diltiazem, fluconazole or sulfonylurea co-administration, and graft to recipient body weight ratio (GRWR).
External evaluation cohort
A total of 572 trough concentrations from 84 patients from 4 to 50 days after transplantation were included in this study. All the demographic and laboratory test data, concomitant medications, and primary diseases collected for the evaluation are summarised in Table 2 . Thirteen observations were below the lower limit of quantification (2.0 ng ml -1 ) and they were included in the analysis as the original reported values. In our dataset, one patient was co-administered diltiazem, five patients were co-administered mycophenolate mofetil, and seven patients were co-administered fluconazole. No patient was co-administered sulfonylureas. In addition, the allele frequencies of CYP3A5*3 genetic polymorphisms are listed in Table 3 and were in Hardy-Weinberg equilibrium. As the ABCB1 genotype was not collected in our data, the genotype of ABCB1 C3435T was assumed to be ABCB1 3435CC, which has the highest frequency in the Chinese population.
External predictability evaluation
Prediction-based diagnostics
The results of prediction-based diagnostics are provided in Figure 1 and Table S1 . None of the investigated models met all the aforementioned standards (MDPE ≤ ± 20%, MAPE ≤ 30%, F 20 ≥ 35%, and F 30 ≥ 50%), indicating unsatisfactory predictive performance. MDPE, as an index of predictive accuracy, was less than ± 20% in six studies (Ji et al. than 30% in all studies. Considering both the accuracy and precision of predictability, the model reported by Zhang et al. (Zhang et al., 2012 ) was superior to the others, with F 20 > 35% and F 30 > 45%.
Simulation-based diagnostics
In simulation-based diagnostics, pvcVPC showed a large discrepancy between the observations and model simulations in all published studies ( Figure S2 ). A significant trend of over-or under-prediction was observed, indicating misspecifications of the models. The relatively superior model by Zhang in the prediction-based diagnosis (Zhang et al., 2012 ) also performed poorly.
The NPDE results are presented in Figure S3 and Table S2 . NPDE distribution of all studies significantly deviated from the standard normal distribution. All models were rejected with no adjusted P values over 0.01 for the global test.
Bayesian forecasting
The results of Bayesian forecasting proved that prior observations significantly improved both predictive precision and accuracy even with only one prior observation. Predictive performance reached a stable state with two or three priors. More number of priors did not achieve further obvious improvement. Furthermore, in this evaluation, the models of Zhang et al. (Zhang et al., 2012 ), Zhu et al. (Zhu et al., 2014) , and Zhu et al. (Zhu et al., 2015) were the best three, which showed MDIPE < 20%, MAIPE < 30%, IF 20 > 35% and IF 30 > 50% under the circumstance of two to four priors. The box plots of predictability are presented in Figure 2 , and the results of IPE% are listed in Table S4 .
Effect of model structures
The model structure employed in all the included studies was either linear 1CMT or 2CMT model. 
)
Where V m denotes the maximum dose rate (daily dose) at the steady state. The Michaelis constant, K m , denotes the steady-state trough concentration at half-maximal dose rate. The estimated parameters for all the three structural models are presented in Table   S3 .
The results of prediction-based diagnostics shown in Figure 3 and Table S1 indicated that the nonlinear MM model performed better than the linear 1CMT and 2CMT models. The F 20 and F 30 of the covariate-free MM model showed an improvement over those of the linear 1CMT (29.72% vs. 25.87% and 25.87%) and 2CMT models (43.01% vs. 38.99% and 40.21%).
The result of Bayesian forecasting listed in Figure 4 and Table S4 showed that the predictive performance of each model was improved with MAPB even with only one prior observation. The predictability reached a stable state with two or three priors and improvement cannot be further achieved with more prior observations. The IF 20 and IF 30 values of the covariate-free MM model after Bayesian forecasting with one prior reached 49% and 74%, respectively, which were considerably better than those of the linear 1CMT model (31% and 46%, respectively) and 2CMT model (29% and 48%, respectively). Furthermore, with two to four priors, the IF 20 and IF 30 values of the covariate-free MM model after Bayesian forecasting were all beyond 35% and 50%, respectively, whereas both linear models failed to attain the criteria of IF 20 ≥ 35% and F 30 ≥ 50%.
Discussion
To the best of our knowledge, this is the first comprehensive external evaluation of published tacrolimus popPK models in adult liver transplant patients using an independent dataset, which was prospectively collected from routine TDM, ensuring the accuracy of the data record.
The results showed that the predictive accuracy was acceptable with MDPE ≤ ± 20% in six studies. However, poor predictive precision was observed, and the MAPE fell outside ± 30% in all the investigated models. Therefore, taking both accuracy and precision into account, the prediction-based predictive performances were unsatisfactory. In addition, the simulation-based pvcVPC and NPDE tests showed that all the published models failed to fulfil the diagnostic criteria.
Considering that the predictive performance depended largely on the model structure and structural model components had a The identified nonlinear kinetics of tacrolimus PK may be partly attributed to its poor aqueous solubility (1-2 μg ml -1 ) (Lee et al., 2016) and low permeability to the intestinal membrane (Tamura et al., 2002) . These lead to a dissolution rate-limited absorption in the gastrointestinal tract, and variable and low oral bioavailability (Lee et al., 2016) . Additionally, the recovery of gastrointestinal function, metabolising enzymes, and P-gp activity with POD, as well as the gradually decreased induction of CYP3A enzymes and P-gp in the liver and intestine by tapering of co-administered steroid doses, may also lead to the nonlinear to the nonlinearity in the distribution and elimination of tacrolimus.
However, the nonlinearity of tacrolimus in liver transplant patients may be different from that in renal transplant patients. In renal transplant patients, with 1-4 prior observations, the IF 20 % and IF 30 % of the covariate-free MM models after MAPB forecasting reached 65%-90% and 94%-100%, respectively, whereas those in liver transplant patients achieved 35%-49% and 57%-74%, respectively. This is most likely due to the poor hepatic function significantly affecting the first-pass metabolism of tacrolimus and different corticosteroid dosage used in patients with liver transplantation (Bekersky et al., 2001 ; Shimomura et al.,
2002; Vanhove et al., 2016a). Additionally, most of the liver transplant recipients included in our study were hepatitis B-positive (n = 61), hepatitis C-positive (n = 3), or hepatitis E-positive (n = 1). Replication of hepatitis virus in hepatocytes alters the CYP3A system, leading to reduced tacrolimus metabolism (Horina et al., 1993) , which is different to that in renal transplant recipients.
Further investigations need to be conducted to explore the underlying mechanism.
Beyond those mentioned above, the TDM effect is also considered a factor leading to nonlinearity. Individuals with higher drug clearance usually have lower drug concentrations. This will make clinicians prescribe higher doses. Therefore, a relationship between dose and clearance will be finally induced during the TDM process, which may be misclassified as nonlinearity ( In addition to the model structures discussed above, covariates may also be responsible for predictive performance (Vanhove et al., 2016a). POD and HCT were the two prevailing covariates identified to affect the CL/F of tacrolimus in liver transplant recipients.
POD was identified as a major surrogate for several time-dependent variables (Ette and Ludden, 1995). The gradual improvement in metabolic function with POD increased the CL/F during the early stage after liver transplantation (Chen et al., 2017) . Therefore, an increase in the dose of tacrolimus was usually required to maintain similar trough concentrations with increasing time after transplantation (Wallin et al., 2011). In addition, tapering of corticosteroid doses with POD is known to decrease the CL/F of tacrolimus, leading to a decrease in the dose of tacrolimus to maintain similar trough concentrations with increasing time after transplantation (Passey et al., 2011). The effect of POD on tacrolimus PK may also be related to other factors.
Their simultaneous inclusion as covariates in the final model would definitely affect the description of POD.
Tacrolimus mainly binds to erythrocytes, and changes in HCT alter the distribution of tacrolimus between blood and fat because it is a lipophilic drug (Sam et al., 2000) . Low HCT values increase the partitioning of tacrolimus into fat, thereby leading to a higher apparent volume of distribution, which reflects a greater availability of unbound tacrolimus for distribution in Staatz, C.E., Willis, C., Taylor, P.J., Lynch, S.V., Tett, S.E., 2003. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 9, 130-137. ALB, albumin (g l -1 ); ALP, alkaline phosphatase (U l -1 ); ALT, alanine aminotransferase (U l -1 ); AST, aspartate transferase (U l -1 ); BOV, between occasion variability; BSV, between subject variability; BUN, blood uric nitrogen (mmol l -1 ) ; WT, body weight (kg); C 0 , blood trough concentration; CL, clearance (l h -1 ); CL/F, apparent clearance (l h -1 ); CCR, creatinine clearance calculated by the Cockcroft-Gault formula (ml min -1 ); CMT, compartment; CYP3A5*1, cytochrome P450 3A5 expresser (*1/*1 or *1/*3); DD, tacrolimus daily dose (mg day -1 ); DDWT, tacrolimus daily dose per kilogram of body weight (mg day -1 kg -1 ); EMIT, enzyme multiplied immunoassay technique; F, bioavailability; GHW, grafted hepatic weight (g); GRWR, graft:recipient weight ratio (%); HB, hemoglobin (g l -1 ); HCT, haematocrit (%); HPLC, high performance liquid chromatography; HT, body height (m); INR, international normalized ratio; IS, intensive sampling; Ka, absorption rate constant (h -1 ); LC-MS/MS, liquid chromatography tandem-mass spectrometry; MEIA, microparticle enzyme immunoassay; POD, postoperative days (day); Q, inter-compartmental clearance (l h -1 ); Q/F, apparent inter-compartmental clearance (l h -1 ); RUV, residual unexplained variability; SCR, serum creatinine (μmol l -l ); SD, standard deviation; SS, sparse sampling; TBIL, Total bilirubin (μmol l -1 ); Tlag, absorption lag time (h); TP, total protein (g l -1 ); V C , volume of distribution of central compartment (l); V C /F, apparent volume of distribution of central compartment (l); V P , volume of distribution of peripheral compartment (l); V P /F, apparent volume of distribution of peripheral compartment (l); a Intensive samples were collected at 0, 1, 2, 4, and 6 or 8 h postdose and repeated on a second occasion (generally 1 to 4 weeks after the first collection day).
b Intensive samples were collected at 0, 1, 2, 4, and 6 h postdose.
c Intensive samples were collected predose and at specific time-points after an oral dose of tacrolimus. But, details and the time points of sampling were not available.
d Intensive samples were collected predose and at 2, 3, 4, 6, and 9 h postdose on day 8 (±2), day 21 (±3), and day 90 (±7) post-transplantation.
e Between subject variability for CL/F in the 0-3 day post-transplantation period.
f Between subject variability for Vd/F in the 4-15 day post-transplantation period. The allele frequencies are found to be in Hardy-Weinberg equilibrium (P > 0.05) 
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DNA was extracted from the whole blood of both liver transplant receipients and their corresponding donors using the TIANamp 
Inclusion criteria:
(1) Original population pharmacokinetic studies on adult liver transplant recipients treated with oral tacrolimus of the immediate-release formulation.
(2) Population pharmacokinetic modeling approach restricted to nonlinear mixed-effects analyses.
(3) Language: English.
Exclusion criteria:
 Receipients were not treated with oral tacrolimus of immediate-release formulation .
 Datasets were overlapped or studies were duplicated.
 Required covariates were unavailable in the evaluation dataset.
 Model details were not available for external evaluation.
Flow diagram of literature selection process.
Lists of the excluded studies (n = 10):
(1) Not treated with oral tacrolimus of immediate-release formulation (n = 1) Among all the identified studies, 62.5 % (n = 10) were reported in East Asian (six in China [8, 10, [12] [13] [14] [15] , two in Korea [16, 26] , one each in Singapore [7] and Japan [1] , respectively), and only 18.8% (n = 3) in Europe (two in France [4, 9] , one in Spain [11] ) and 18.8% (n = 3) in Australia [2, 3, 5] (Figure S1A ).
Most of the included studies (87.5%) were single centre studies [1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] while only 12.5% were multicentre studies [2, 3] .
Moreover, 43.8% (n = 7) of the studies had a small sample size of less than 50 patients [1, 3, 4, 6, 7, 9, 12] , 37.5% (n = 6) of the studies used data from patients between 50 and 100 subjects [2, 5, 8, 11, 14, 16] , and only 18.8% (n = 3) of the studies involved more than 100 participants [10, 13, 15] (Figure S1B ).
Three kinds of bioassays were employed in previous studies, including MEIA in eleven studies [1, 4-6, 8, 10-14, 16] , LC-MS in three studies [2, 3, 7] , EMIT in one study [9] , and LC-MS combined with MEIA in one study [15] (Figure S1C ).
Additionally, the post-transplant period of follow-up varied greatly from one day to 2115 days after the liver transplantation ( Figure S1D ). Over half of the studies (62.5%, n = 10) were conducted during the first 6 months post-transplantation [1, 4, 5, 8, 9, 11-13, 15, 16] , two of those were performed within 2 weeks post-transplantation [11, 16] . Others were conducted over six months post-transplantation. Only one study did not report the postoperative period [7] . a Data are presented as P value *** P < 0.001, ** P < 0.01, * P < 0.05
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